Gal3′s role in psoriasis was discovered unexpectedly during the NASH clinical trial with Gal3 inhibitor, GR-MD-02 where moderate to severe plaque psoriasis was effectively treated (ClinicalTrials.gov (accessed on 19 February 2023) Identifier: NCT01899859). This evidence concerns the gene LGALS3 and metabolic dysfunction-associated steatohepatitis.